Immunohistochemical staining of E-Cadherin  of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

E-Cadherin [EP6] Antibody (cGMP).

$ 135.00$ 745.00
Please Select Product Options Below To View The Catalog Number.

Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Rabbit Rabbit IgG

Product NumberDescriptionPrice
QIVD125-0.1ml Size: 0.1 ml, Format: Concentrate $ 135.00
QIVD125-0.5ml Size: 0.5 ml, Format: Concentrate $ 465.00
QIVD125-1ml Size: 1 ml, Format: Concentrate $ 745.00
QIVD125-6ml Size: 6 ml, Format: Predilute $ 365.00
Shipping Information
In Stock
Flat Rate Shipping Anywhere in the US: $45
Datasheets and Documentation
Product Datasheet
Certificate of Analysis and Tags (Coming Soon)
Lot Number:

Expiration Date:

Concentration (Write Lyophilized if Lyophilized):

Reconsitution Instructions (Leave Blank if Liquid):

Manufacture Date:


Bioactivity (test results eg. IU/ml):

SKU: QIVD125-0.1ml
E-Cadherin General Information
Alternate Names
Molecular Weight
97.5 kDa
Chromosomal Location
q22.1 [chr: 16] [chr_start: 68737292] [chr_end: 68835541] [strand: 1]
Curated Database and Bioinformatic Data
Gene SymbolCDH1
Entrez Gene ID999
RefSeq Protein Accession(s)NP_004351; NP_001304115; NP_001304113; NP_001304114
RefSeq mRNA Accession(s); NM_001317184; NM_001317186; NM_004360; NM_001317185
RefSeq Genomic Accession(s)NG_008021; NC_000016
UniProt ID(s)P12830
PharmGKB ID(s)PA26282
KEGG Gene ID(s)hsa:999
Associated Diseases (KEGG IDs)Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. {ECO:0000269|PubMed:10319582, ECO:0000269|PubMed:12216071}. Disease susceptibility is associated with variations affecting the gene represented in this entry. Heterozygous CDH1 germline mutations are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.; Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Disease susceptibility is associated with variations affecting the gene represented in this entry.; Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:8075649}. Disease susceptibility is associated with variations affecting the gene represented in this entry.; Breast cancer, lobular (LBC) [MIM:137215]: A type of breast cancer that begins in the milk-producing glands (lobules) of the breast. {ECO:0000269|PubMed:17660459}. The gene represented in this entry may be involved in disease pathogenesis.; Blepharocheilodontic syndrome 1 (BCDS1) [MIM:119580]: A form of blepharocheilodontic syndrome, a rare autosomal dominant disorder. It is characterized by lower eyelid ectropion, upper eyelid distichiasis, euryblepharon, bilateral cleft lip and palate, and features of ectodermal dysplasia, including hair anomalies, conical teeth and tooth agenesis. An additional rare manifestation is imperforate anus. There is considerable phenotypic variability among affected individuals. {ECO:0000269|PubMed:28301459}. The disease is caused by mutations affecting the gene represented in this entry.
General Description of E-Cadherin .
E-Cadherin is a transmembrane glycoprotein, plays an important role in epithelial cell adhesion. A decreased expression of E-Cadherin is associated with metastatic potential and poor prognosis in breast cancer and esophagus cancer. In combination with antibody against p120 Catenin or Cytokeratin, E-Cadherin antibody is useful for the differentiation between ductal (E-Cadherin positive) and lobular (E-Cadherin negative) breast carcinomas. It may also help in diagnosis of mesothelioma.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Specification Recommendation
Recommended Dilution (Conc) 1:50-1:100
Pretreatment Citrate Buffer pH 6.0
Incubation Parameters 30 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Monoclonal
Anti-E-Cadherin Antibody Clone: EP6
Host and Isotype: Rabbit Rabbit IgG
Recommended Positive Control Sample: Colon carcinoma
Cellular Localization of Antibody EP6 Staining: Cytoplasmic, cell membrane
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: A synthetic peptide corresponding to residues in the 5th cadherin domain of human E-Cadherin protein
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

E-Cadherin Information for Pathologists


Epithelial calcium-dependent cell adhesion protein. Calcium dependent transmembrane epithelial protein that promotes intercellular adhesion. Its loss is associated with invasive carcinoma. Tumor suppressor gene CDH1 is at 16q22.1. Abnormal function in carcinomas may facilitate cellular detachment leading to metastasis.

Common Uses By Pathologists:

Distinguish LCIS from DCIS in indeterminate cases (Am J Surg Pathol 2001;25:229). Marker of immature erythroid precursors (Am J Clin Pathol 2014;141:656). Microscopic (histologic) images Images hosted on other servers:. Missing Image.

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.

Be the first to review “E-Cadherin [EP6] Antibody (cGMP).”

Your email address will not be published. Required fields are marked *

Share a Protocol (View Reviewed Protocols Below)

Protocol Title




  protocol submission gif
enQuire Bio, LLC   8420 S Continental Divide Rd, #202   Littleton, CO 80127
Chat: See lower right corner. | | Fax: 1-720-897-3730
Customer Service Available M-F 8AM-6PM MST or 24/7 Via Email

E-Cadherin [EP6] Antibody (cGMP).